What's Hot
View all perspectives
TheDaoIndex KDAO2011
3 years 1 month ago
@ACRheum This 👇👇👇idea from @nighat
I moderated a panel of women leaders in a virtual world - one of the attendees is a trainee from a 3rd world country and had a hard time finding ways to get help/collaboration for research studies; she wanted to know what she could do #ACR21 https://t.co/4Jn8jYUXME
EnvisionRheumat ERheumat
3 years 1 month ago
#ACR21
new 2022 classification criteria by ACR/EULAR for AAV
💥GPA-Sensitivity-92%, Specificity-94%
💥MPA-Sensitivity-91%, Specificity-94%
💥EGPA-Sensitivity-85%, Specificity-99%
💥Score based https://t.co/61SOl4Tovg
swethaann23 swethaann23
3 years 1 month ago
Reasons for COVID-19 vaccine hesitancy in rheumatology pts in southeast US based on survey study:
🔰Vaccine being “rushed” or “experimental”
🔰Safety of vaccine in the patients’ rheumatologic diagnoses
🔰Side effects
🔰Concern for Allergic reaction
Abst#1589 #ACR21 @RheumNow https://t.co/xm15KxdA56
Pedro Castillo _Castillo_Pedro
3 years 1 month ago
Upadacitinib PsA w/axial involvement - post-hoc analysis of SELECT-PsA 1 and S-PsA-2
Statistically greater response in axial dz compared to placebo in both dz dx'ed by investigator alone & on investigator + PRO-based criteria
https://t.co/YPc5fx9wAR
#ACR21 Abst1945 @RheumNow
swethaann23 swethaann23
3 years 1 month ago
Retrospective chart review of rheumatic irAE patients:
Persistent rheumatic irAE activity 🔼received GC
Inflammatory arthritis pts 🔼risk of persistent rheumatic irAE
Risk factors for mortality➡️tumor progression➕ continued Rx GC at last follow-up
Abst#1516 #ACR21 @RheumNow https://t.co/KusNaVlEXp
Pedro Castillo _Castillo_Pedro
3 years 1 month ago
Dr. Alexis Ogdie on opioid use in PsA and axSpA, highlighting need for better interventions.
🔹21% of PsA pts (n=828) and 27% of axSpA (n=334) reported prescription opiate use.
🔹⬆️BASDI & HAQ-DI =>⬆️opiate use & costs
https://t.co/Id658ocDVf
#ACR21 Abst1777 @RheumNow
sheila RHEUMarampa
3 years 1 month ago
Prof. Ami Shah: Patients with #scleroderma have an ⬆ risk of #cancer vs. general population
📌Data from 3 recent meta-analysis: Scleroderma pts have 1.4 to 1.8 fold increased risk of cancer
@RheumNow #ACR21 https://t.co/4uQN6y3tIn
sheila RHEUMarampa
3 years 1 month ago
Dr. Ami Shah shares her approach to cancer screening in patients with #scleroderma👇
@RheumNow #ACR21 https://t.co/chmlGe4iyl
sheila RHEUMarampa
3 years 1 month ago
TIF1-y: most dominant target in #cancer assoc'd #dermatomyositis
🔷Associated with cancer in every racial group tested; no assoc'n w/ juvenile DM
@RheumNow #ACR21 https://t.co/rPg1CQuNka
Dr. John Cush RheumNow
3 years 1 month ago
Factors Associated with Poor Vaccine Response in Rituximab: Dr. Yuzaiful Yusof (@Yuz6Yusof) discusses abstract #0437 presented at the #ACR21 annual meeting.
https://t.co/T0PFiZlbTa https://t.co/idj5T7j7ke
Dr. John Cush RheumNow
3 years 1 month ago
JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease
Dr. Bella Mehta ( @bella_mehta) shares abstract findings from #ACR21.
https://t.co/4FyXX5JIyZ https://t.co/YAJOwvLbLS
Dr. John Cush RheumNow
3 years 1 month ago
Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE from Dr. Yuz Yusof ( @Yuz6Yusof)
It's almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under EUA. But is the vaccine safe for people with lupus?
https://t.co/i3HeCvS6El https://t.co/Tn0nWKrK4T
swethaann23 swethaann23
3 years 1 month ago
AxSpA/ PsA pts who completed ePRO Q between 2018-2021 showed 🔽 trend of PRO mostly in pts on biologic Rx
If ASDAS < 1.3 /PSAID-12 < 2➡️ pts were seen less frequently
⭐️🔽 clinic workload and better disease activity stratification
Abst # 1788 #ACR21 @RheumNow #ACRBest https://t.co/ilSrOjHQAk
Poster Hall